Working… Menu
Trial record 4 of 5 for:    G207

G207 Followed by Radiation Therapy in Malignant Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00157703
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : December 16, 2008
National Cancer Institute (NCI)
Information provided by:

Brief Summary:

This is an open-label, single site study to evaluate the safety and tolerability of intratumoral administration of G207 followed by treatment with radiation therapy in patients with recurrent/progressive malignant glioma.

This study is a two stage phase 1 study, in which a de-escalating dosing scheme will be used, i.e. the first patients will receive the higher dose and if excessive toxicity occurs, the dose will be reduced for the following patients. The purpose of the dose de-escalation phase is to find the best safe dose of G207.

In the first stage of the study, treatment with G207 will be followed by focal radiation therapy on the following day, and in the second stage treatment with G207 will be followed by gamma knife surgery also on the following day.

All patients will return to the clinic 28 days and 3, 6, 9 and 12 months after G207 administration at which time clinical assessments will be performed, and will be followed for safety and survival at clinic visits or by telephone every 3 months for up to 2 additional years and annually thereafter.

Condition or disease Intervention/treatment Phase
Malignant Glioma Drug: G207 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Staged Phase 1 Study of the Treatment of Malignant Glioma With G207, a Genetically Engineered HSV-1, Followed by Radiation Therapy
Study Start Date : May 2005
Actual Primary Completion Date : October 2008
Actual Study Completion Date : December 2008

Intervention Details:
  • Drug: G207
    1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)

Primary Outcome Measures :
  1. Adverse events [ Time Frame: from 1st dose to end of study visit ]

Secondary Outcome Measures :
  1. Radiographic response [ Time Frame: Withdrawal or death of last patient ]
  2. Performance scale [ Time Frame: Last patient out ]
  3. Overall survival [ Time Frame: Withdrawal or death of last patient ]
  4. Immune response [ Time Frame: Last patient out ]
  5. Presence of G207 in blood and saliva [ Time Frame: Last patient out ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Pathologically proven residual/recurrent glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma which is progressive despite radiotherapy or chemotherapy
  2. Failed external beam radiotherapy > 5,000 CGy at least 4 weeks prior to enrollment
  3. Residual/recurrent lesion must be ≥ 1.0 cm and (for Stage 2 only) ≤ 4 cm in diameter as determined by magnetic resonance imaging (MRI)
  4. Normal hematological, renal and liver function

    • Absolute neutrophil count > 1500/mm3
    • Platelets > 100,000/mm3
    • Prothrombin time (PT) or partial thromboplastin time (PTT) < 1.3 x control
    • Creatinine < 1.7 mg/dl
    • Total bilirubin < 1.5 mg/dl
    • Transaminases < 4 times above the upper limits of the institutional norm
  5. Karnofsky Performance Status score ≥ 70
  6. Age > 19 years-old
  7. Capable of giving informed consent
  8. Must be willing to practice an effective barrier method of birth control for 2 months post G207 inoculation, whether male or female
  9. Females of childbearing potential: negative pregnancy test within 24 hours prior to G207 administration

Exclusion Criteria:

  1. Surgical resection within 4 weeks of enrolment
  2. Acute infection, granulocytopenia or medical condition precluding surgery
  3. Pregnant or lactating females
  4. History of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
  5. Tumor involvement which would require ventricular, brainstem, basal ganglia, or posterior fossa inoculation or would require access through a ventricle in order to deliver treatment or tumor involving both hemispheres or with subependymal/cerebral spinal fluid (CSF) dissemination
  6. Tumor position that could, in the Investigator's opinion, pose the risk of penetration of the cerebral ventricular system during inoculation with the study drug (Note: If penetration of the ventricular system is suspected or confirmed, G207 administration must be aborted.)
  7. Tumor locations that would expose the patient to unacceptable risk with radiation therapy
  8. Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpesvirus protocol)
  9. Prior participant in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment
  10. Required steroid increase within 2 weeks prior to injection
  11. HIV seropositive
  12. Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir)
  13. Active oral or genital herpes lesion
  14. Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc.
  15. Radiation treatment volume of greater than 4 cm maximum diameter (Stage 2 only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00157703

Layout table for location information
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3410
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Study Director: Axel Mescheder, M.D. Medigene AG
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alice Chen, MediGene Identifier: NCT00157703    
Other Study ID Numbers: CT2001
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: December 16, 2008
Last Verified: December 2008
Keywords provided by MediGene:
Malignant glioma
Glioblastoma multiforme
Anaplastic astrocytoma
Brain cancer
Brain tumor
recurrent/progressive malignant glioma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue